Kikkeri N. Naresh, M.B.B.S., D.C.P., M.D., FRCPath

Dr. Kikkeri N. Naresh M.B.B.S., DCP, M.D., FRCPath
Faculty Member

Kikkeri N. Naresh, M.B.B.S., D.C.P., M.D., FRCPath

Professor
Clinical Research Division, Fred Hutch

Section Head, Pathology
Clinical Research Division, Fred Hutch

Fax: 206.606.1345
Mail Stop: G7910

Dr. Kikkeri Naresh is a pathologist, an expert in the laboratory analysis of tissue samples for diagnosis or other medical purposes. He specializes in hemopathology — the pathology of blood tissues — especially lymphoma and bone marrow pathology. As a translational researcher, Dr. Naresh conducts laboratory studies to improve patient care. His focus is the biology of lymphoma, including its genome, formation and cellular environment (or microenvironment). He also develops new algorithms to improve lymphoma diagnosis and precision medicine. His other research interests include lymphoma-causing viruses, blood stem cell transplantation and plasma cell myeloma.

Contact by phone
Academic queries: 206.667.1286 
Clinical queries: 206.606.1343 

Other Appointments & Affiliations

Professor, Department of Laboratory Medicine & Pathology
University of Washington School of Medicine

Pathologist
Seattle Cancer Care Alliance

Visiting Professor
Imperial College London, UK

Education

Royal College of Pathologists London, UK, 2008, FRCPath -Haematology, by published work

Specialist Training Authority (STA) of the Royal Colleges certified specialist in Histopathology (Anatomic Pathology; Board certification equivalent), London, UK, 2003

Royal College of Pathologists London, UK, 2001, MRCPath -Haematology, by published work

Jawaharlal Institute of Postgraduate Education & Research (JIPMER), Pondicherry, India, 1988, M.D. –Pathology (Board certification equivalent)

Government Medical College, Mysore, India, 1985, Diploma in Clinical Pathology (D.C.P.)

Government Medical College, Mysore, India, 1980, M.B.B.S (M.D. equivalent)

Research Interests

Lymphoma biology: Genomics of various lymphomas; Early steps and lesions in lymphomagenesis and pathways of evolution; biology of Immune deficiency lymphoid proliferations including proliferations in post-transplant and HIV setting; biology of Hodgkin lymphoma

Lymphoma diagnosis and precision medicine: Developing diagnostic and precision medicine algorithms using contemporary technologies; biomarker discovery

Tumor microenvironment: Lymphomas & lymphoproliferative disorders and other hematological malignancies

Biology of oncogenic viruses: in lymphomagenesis and patient outcomes

Immune biology of hematopoietic stem cell transplantation Disease evolution following stem cell transplantation

Epidemiology and molecular epidemiology of lymphomas and hematological malignancies

Translational research in plasma cell myeloma

Clinical Expertise

Pathology of lymphomas and lymphoproliferative disorders – histology, immunohistochemistry, genetics and genomics – integrated diagnosis

Bone marrow pathology – morphology, immunohistochemistry, immunophenotyping (flow cytometry), genetics and genomics – integrated diagnosis

Transplantation pathology – diagnosis of diseases and conditions after hematopoietic stem cell transplantation

Cancer pathology

Current Studies

2020-2022
Project Title: Lymphomas and its precursors in the Consortium’s 13-county catchment area – understanding differences between counties and comparison with nation-wide data
Grant Type: Catchment Area Pilot Award from Cancer Center Support
Role: Co-Investigator (PI: Teresa Hyun, MD PhD)
Goal: Lymphoma incidence varies between the 13 counties – age-adjusted incidence rate (2014-2018) is lowest in San Juan (17.1) and highest in Grays Harbor (30.2). As lymphoma is not a single disease, it is likely that the differences in incidence of individual lymphoma types is far more staggering. We are addressing the questions: a) Given the known differences in the incidence rate between the 13 counties of the consortium, are there significant differences in the incidence of specific lymphoma type/s? b) Will such differences translate to differences in the prevalence of lymphoma precursors? c) Could an infective or an environmental agent be causally associated with these differences?

External Committees/Collaboration

2018- Pathology Lead, project on multi-omics of WHO categories of haematological malignancies – Duke Univ. USA with >12,000 samples

2020- Member, Scientific Advisory Committee, Lister Institute, UK

2020- Member of the Scientific Advisory Board (SAB) for the National Medical Research Council (NMRC) Singapore’s programme titled “The Singapore lYMPHoma translatiONal studY (SYMPHONY)”

2020- Member, International Committee & International Regional Advisor for the Americas – Royal College of Pathologists, UK

2020- Invitation by the WHO to contribute chapters on lymphoma to the classification of urological and male genital organs neoplasms.

Find a Clinical Trial

For the Media

The Media Relations team at Fred Hutch is available to assist members of the news media who would like to arrange interviews with faculty.

Email media@fredhutch.org or call 206.667.2210.